Oxilio
Repurposes and reformulates existing drugs to develop cancer treatments for patients with unmet needs
Highlights
- New on EvolcAdded 2026-11-14
About Oxilio
Oxilio identifies, repurposes and commercialises existing drugs for unmet needs in cancer therapy. Its work also includes drug reformulation and modelling and simulation to inform development and dosing.
The company is a pharmaceutical drug development business focused on oncology. It is headquartered in London, United Kingdom, and was founded in 2019.
Product: Drug repurposing, reformulation and modelling and simulation for cancer treatment development.
Jobs at Oxilio
Leadership
- Ralph Browning · Co-CEOSource: company website
- Simon Yaxley · Co-CEOSource: company website
More biotech & pharma companies
Oxsonics
Clinical-stage drug delivery company developing SonoTran, an ultrasound platform that boosts anti-cancer drug penetration into solid tumoursPangea Botanica
Develops TrkB-activating drug candidates for central nervous system disordersNew on EvolcParticology
Contract particle science and solid form services for pharma teams taking small-molecule drugs to formulated productsYoung companyNew on EvolcPartitionbio
Non-viral cell delivery reagents and technology for life-sciences researchers and biotech companiesNew on EvolcPathios Therapeutics
Develops GPR65-targeting cancer immunotherapies for patients with solid tumorsPencil Biosciences
Synthetic gene-editing technology for therapeutic development and cell-line engineeringNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Content management
- WixHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- ReactMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Page markupsoftware structure signature
- Page markupsoftware structure signature
- Page markupsoftware structure signature
Monitoring
- SentryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.